168 related articles for article (PubMed ID: 7579429)
1. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity.
Bernstein ZP; Porter MM; Gould M; Lipman B; Bluman EM; Stewart CC; Hewitt RG; Fyfe G; Poiesz B; Caligiuri MA
Blood; 1995 Nov; 86(9):3287-94. PubMed ID: 7579429
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-4 in the treatment of AIDS-related Kaposi's sarcoma.
Tulpule A; Joshi B; DeGuzman N; Espina BM; Mocharnuk R; Prakash O; Templeton D; Levine AM; Gill PS
Ann Oncol; 1997 Jan; 8(1):79-83. PubMed ID: 9093711
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.
Meropol NJ; Barresi GM; Fehniger TA; Hitt J; Franklin M; Caligiuri MA
Cancer Immunol Immunother; 1998 Aug; 46(6):318-26. PubMed ID: 9756416
[TBL] [Abstract][Full Text] [Related]
4. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer.
Shah MH; Freud AG; Benson DM; Ferkitich AK; Dezube BJ; Bernstein ZP; Caligiuri MA
Clin Cancer Res; 2006 Jul; 12(13):3993-6. PubMed ID: 16818697
[TBL] [Abstract][Full Text] [Related]
6. Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies.
Khatri VP; Fehniger TA; Baiocchi RA; Yu F; Shah MH; Schiller DS; Gould M; Gazzinelli RT; Bernstein ZP; Caligiuri MA
J Clin Invest; 1998 Mar; 101(6):1373-8. PubMed ID: 9502779
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma.
Choi BS; Sondel PM; Hank JA; Schalch H; Gan J; King DM; Kendra K; Mahvi D; Lee LY; Kim K; Albertini MR
Cancer Immunol Immunother; 2006 Jul; 55(7):761-74. PubMed ID: 16187086
[TBL] [Abstract][Full Text] [Related]
8. A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients.
Sosman JA; Fisher SG; Kefer C; Fisher RI; Ellis TM
Ann Oncol; 1994 May; 5(5):447-52. PubMed ID: 7521206
[TBL] [Abstract][Full Text] [Related]
9. Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity.
Meropol NJ; Porter M; Blumenson LE; Lindemann MJ; Perez RP; Vaickus L; Loewen GM; Creaven PJ; Wilkes KA; Giedlin MA; Caligiuri MA
Clin Cancer Res; 1996 Apr; 2(4):669-77. PubMed ID: 9816217
[TBL] [Abstract][Full Text] [Related]
10. Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity.
Jacobson EL; Pilaro F; Smith KA
Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10405-10. PubMed ID: 8816813
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
12. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity.
Caligiuri MA; Murray C; Soiffer RJ; Klumpp TR; Seiden M; Cochran K; Cameron C; Ish C; Buchanan L; Perillo D
J Clin Oncol; 1991 Dec; 9(12):2110-9. PubMed ID: 1960552
[TBL] [Abstract][Full Text] [Related]
13. Lack of antitumor activity and intolerance of interleukin-4 in patients with advanced HIV disease and Kaposi's sarcoma.
Miles SA; Testa M; Huang J; Wade M; Carden J; Scadden DT
J Interferon Cytokine Res; 2002 Nov; 22(11):1143-8. PubMed ID: 12513914
[TBL] [Abstract][Full Text] [Related]
14. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
Caligiuri MA; Murray C; Robertson MJ; Wang E; Cochran K; Cameron C; Schow P; Ross ME; Klumpp TR; Soiffer RJ
J Clin Invest; 1993 Jan; 91(1):123-32. PubMed ID: 7678599
[TBL] [Abstract][Full Text] [Related]
15. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Farag SS; George SL; Lee EJ; Baer M; Dodge RK; Becknell B; Fehniger TA; Silverman LR; Crawford J; Bloomfield CD; Larson RA; Schiffer CA; Caligiuri MA
Clin Cancer Res; 2002 Sep; 8(9):2812-9. PubMed ID: 12231521
[TBL] [Abstract][Full Text] [Related]
16. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
Soiffer RJ; Murray C; Shapiro C; Collins H; Chartier S; Lazo S; Ritz J
Clin Cancer Res; 1996 Mar; 2(3):493-9. PubMed ID: 9816195
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of subcutaneous recombinant interleukin-2 in patients with advanced HIV disease while on zidovudine.
McMahon DK; Armstrong JA; Huang XL; Rinaldo CR; Gupta P; Whiteside TL; Pazin GJ; Tripoli C; Ho M
AIDS; 1994 Jan; 8(1):59-66. PubMed ID: 8011237
[TBL] [Abstract][Full Text] [Related]
18. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.
Atzpodien J; Kirchner H; Körfer A; Hadam M; Schomburg A; Menzel T; Deckert M; Franzke A; Volkenandt M; Dallmann I
Tumour Biol; 1993; 14(6):354-9. PubMed ID: 8265981
[TBL] [Abstract][Full Text] [Related]
19. Beta-interferon therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). A phase II trial with preliminary evidence of antiviral activity and low incidence of opportunistic infections.
Miles SA; Wang HJ; Cortes E; Carden J; Marcus S; Mitsuyasu RT
Ann Intern Med; 1990 Apr; 112(8):582-9. PubMed ID: 2109563
[TBL] [Abstract][Full Text] [Related]
20. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation.
Soiffer RJ; Murray C; Cochran K; Cameron C; Wang E; Schow PW; Daley JF; Ritz J
Blood; 1992 Jan; 79(2):517-26. PubMed ID: 1730094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
